- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05386953
Intraoperativ normal saltvannsadministrasjon og akutt nyreskade hos pasienter som gjennomgår levertransplantasjon
Intraoperativ normal saltvannsadministrasjon og akutt nyreskade hos pasienter som gjennomgår levertransplantasjon: en retrospektiv kohortstudie
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Liver transplantation requires a long operation time and is often associated with a significant amount of surgical bleeding. It is common for the anesthesiologist to infuse large amounts of fluid or blood products due to bleeding, hemodynamic instability, or ascites drainage. Therefore, in the anesthesia for liver transplantation, optimal management of fluid administration is necessary and the choice of the type of crystalloid may affect the prognosis or the incidence of postoperative complications of patients.
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Seoul, Sør -Korea, 03080
- Seoul National University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients received liver transplantation surgery in a single tertiary care university hospital
Beskrivelse
Inclusion Criteria:
- Consecutive patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2004 and 2018
Exclusion Criteria:
- patients with baseline renal dysfunction of hepatorenal syndrome or chronic kidney disease
- missing preoperative serum creatinine value
- missing other baseline or outcome variables
- patients who received retransplantation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Balanced group
Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery |
Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Andre navn:
|
|
Saline group
Patients who received only normal saline during liver transplantation surgery |
Patients received normal saline as a maintenance crystalloid during liver transplantation surgery. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Acute kidney injury
Tidsramme: the first 7 postoperative days
|
The investigators defined acute kidney injury by the KDIGO (Kidney Disease Improving Global Outcomes) criteria, which was determined according to the greatest change in serum creatinine level during the postoperative seven days (Stage 1: more than 1.5-fold; stage 2: more than 2-fold; stage 3: more than 3-fold increase of baseline or increase in SCr to ≥ 4.0 mg/dL or the initiation of renal replacement therapy). The most recent SCr level measured before surgery was collected as a baseline value. |
the first 7 postoperative days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of postoperative hemodialysis
Tidsramme: the first month after admission
|
the incidence of new-onset postoperative hemodialysis during hospitalization |
the first month after admission
|
|
Early allograft dysfunction
Tidsramme: the first 7 postoperative days
|
One or more of the following are present within the first 7 postoperative days: total bilirubin ≥ 10 mg/dL, PT (prothrombin time):INR (international normalized ratio)≥ 1.6, or AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 2000 IU/L |
the first 7 postoperative days
|
|
In-hospital mortality
Tidsramme: the first month after admission
|
all-cause mortality during hospitalization |
the first month after admission
|
|
One-year mortality
Tidsramme: one year after transplantation
|
all-cause mortality during one year after transplantation |
one year after transplantation
|
|
Length of intensive care unit stay
Tidsramme: the first month after admission
|
Length of intensive care unit stay after transplantation |
the first month after admission
|
|
Length of hospital stay
Tidsramme: the first month after admission
|
Length of hospital stay after transplantation |
the first month after admission
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Won Ho Kim, MD, PhD, Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdommer i fordøyelsessystemet
- Leversykdommer
- Leversvikt
- Leverinsuffisiens
- Fibrose
- Patologiske tilstander, tegn og symptomer
- Levercirrhose
- Sluttstadium leversykdom
- Farmasøytiske preparater
- Krystalloidløsninger
- Isotoniske løsninger
- Løsninger
- Saltoppløsning
- Ringers laktat
- stable plasma protein solution
Andre studie-ID-numre
- H-2108-173-1248
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .